Clinical and translational melanoma research – Hanna Eriksson's Group

Our overall objective is to optimally inform clinical decision-making and improve the outcome in all stages of melanoma. The research has a clear clinical  and translational approach by using large-scale register data, recent technical advances including artificial intelligence and multi-omics analyses in a real-world environment and within clinical trials. Specifically, we focus on the interplay in immune tumor immune microenvironment to identify factors blocking the synergy between therapies.

Portrait of Hanna in her doctor´s clothes.
Hanna Eriksson. Photo: Ulf Sirborn

Our research

Our overall objective is to optimally inform clinical decision-making and improve the outcome from early disease to advanced melanoma. The research has a clear clinical  and translational approach by using large-scale register data, recent technical advances including artificial intelligence and multi-omics analyses in a real-world environment and within clinical trials. Specifically, we focus on the interplay between the immune system and the tumor immune microenvironment to identify factors blocking the synergy between therapies.

Several key questions remain to increase the clinical outcome in melanoma: 1) poorly understood survival differences in sub-groups of melanoma patients; 2) lack of effective strategies to overcome resistance to immunotherapy and immune-related toxicities; 3) limited knowledge of treatment outcomes in a real-world environment.

Projects

  • Artificial Intelligence in Melanoma Diagnostics -  the AIDMel trial.
  • Large-scale register analyses to investigate risk and survival in melanoma focusing on common drugs with a potential immunomodulatory effect and loss of life expectancy in melanoma.
  • Real-world outcome analyses of melanoma therapies.
  • Treatment predictive and prognostic biomarkers in melanoma with a specific foucs on brain metastastic disease and mucosal melanoma.
  • Novel strategies to resensitise resistant melanoma to standard immunotherapy by augmenting anti-melanoma immune responses.
  • Validation of underlying molecular resistance mechanisms to immune therapies in vitro, and to test the efficacy of novel interventions in animal models.
  • Gender Differences in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment - the G-DEFINER trial.
  • Development of a Quality of Life Module for Patients with Advanced Melanoma (EORTC QoL Melanoma Module)

Funding

  • The Swedish Research Council.
  • The Swedish Cancer Society.
  • Horizon 2020; GenderNet-Plus.
  • Radiumhemmet Research Funds.
  • Stockholm Regional Council.
  • Translational Seed Funding Grant.
  • Karolinska Institutet.
  • The Swedish Medical Society.
  • Cancer- och Allergi Fonden

 

Publications

Selected publications